At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 343 enrolled
Drug / intervention
treatment +1 moredrug
Likely dose
treatment 250mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 3, Randomized, Open-label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated Patients With Non-squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (Alk) Gene Locus.
In Brief
A Phase 3 clinical trial evaluating treatment for Non Squamous Lung Cancer. Completed, enrolled 343 participants across 249 sites in 31 countries.
Detailed Summary
This study will evaluate the anti-cancer effects of crizotinib when compared with standard chemotherapy in patients with ALK positive lung cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Squamous Lung Cancer
CountriesAustralia, Austria, Belgium, Brazil, Canada, Chile, China, Finland, France, Germany, Hong Kong, India, Ireland, Italy, Japan, Luxembourg, Mexico, Netherlands, Norway, Peru, Portugal, Russia, Singapore, South Africa, South Korea, Spain, Switzerland, Taiwan, Ukraine, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJun 2010
Enrollment StartJan 2011
Primary CompletionNov 2013
Study CompletionNov 2016
TodayJul 2026
First PostedJun 30, 2010
Enrollment StartJan 13, 2011
Primary CompletionNov 30, 2013
Study CompletionNov 30, 2016
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 16.0 years ago
Interventions
treatmentdrug
crizotinib 250mg orally continuous twice daily dosing
treatmentdrug
pemetrexed 500mg/m2 IV day 1 plus cisplatin 75mg/m2 IV day 1 every 21 days OR pemetrexed 500mg/m2 IV day 1 plus carboplatin AUC 5 or 6 day 1 every 21 days investigator's choice